Brief: Imugene Says Cel Granted FDA Fast Track Designation In Blood Cancer DLBCL
19/03/2025 01:15
March 19 (Reuters) - Imugene IMU.AX: AZER-CEL GRANTED FDA FAST TRACK DESIGNATION IN BLOOD CANCER DLBCL Further company coverage: IMU.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement